Rigel Pharmaceuticals Inc (STU:RI2A)
€ 0.826 0.002 (0.24%) Market Cap: 157.65 Mil Enterprise Value: 167.84 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 66/100

Q4 2019 Rigel Pharmaceuticals Inc Earnings Call Transcript

Feb 27, 2020 / 09:30PM GMT
Release Date Price: €1.95 (-0.51%)
Operator

Greetings, and welcome to Rigel Pharmaceuticals' Financial Conference Call for the Fourth Quarter and Year-end 2019. (Operator Instructions) As a reminder, this conference is being recorded.

It is now my pleasure to introduce a speaker, Dolly Vance, who is Rigel's Executive Vice President, Corporate Affairs and General Counsel. Thank you, Ms. Vance, you may begin.

Dolly A. Vance
Rigel Pharmaceuticals, Inc. - Executive VP of Corporate Affairs, General Counsel & Corporate Secretary

Welcome to our fourth quarter and full year 2019 financial results and business update conference call. The financial press release for the fourth quarter was issued a short while ago and can be viewed, along with the accompanying slides through this presentation, in the News and Events section of our Investor Relations page on our website, www.rigel.com.

As a reminder, during today's call, we may make forward-looking statements regarding our financial outlook and our plans and timing for regulatory

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot